Is high-dose glucocorticoid beneficial in COVID-19? Source: Eur Respir J, 57 (4) 2100065; 10.1183/13993003.00065-2021 Year: 2021
Investigating the steroids and long-acting β2-agonists combination: why do we need more? Source: Eur Respir J 2004; 23: 501-502 Year: 2004
Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where? Source: Eur Respir J 2011; 38: 947-958 Year: 2011
Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma Source: International Congress 2019 – Powerful cohort studies with/without lung function Year: 2019
Reply: Fixed breathing protocols in multiple-breath-washout testing: truly an option in children? Source: Eur Respir J, 57 (3) 2100189; 10.1183/13993003.00189-2021 Year: 2021
Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
Does inhaled corticosteroid use affect the risk of ?COVID-19-related death? Source: Breathe, 17 (1) 200275; 10.1183/20734735.0275-2020 Year: 2021
Anti-inflammatory therapy COPD: fenspiride and(or) theophylline versus inhaled corticosteroids? Source: Annual Congress 2007 - Treatment of COPD Year: 2007
Late Breaking Abstract: Fluticasone/salmeterol combination confers significant benefits in smoking asthmatics Source: Annual Congress 2010 - Smoking related diseases, damages due to environmental tobacco smoke and smoking control strategies Year: 2010
Optimising bronchodilator therapy in COPD: Who, why and when? Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care Year: 2019
Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Inhaled corticosteroids in COPD: friend or foe? Source: Eur Respir J, 52 (6) 1801219; 10.1183/13993003.01219-2018 Year: 2018
Dehydroepiandrosterone in the treatment of steroid resistant asthma: Whether synthetic nanoform can replace the natural hormone? Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma? Source: Eur Respir Rev 2015; 25: 54-64 Year: 2016
Systemic treatment: an adjuvant indication? Source: Annual Congress 2004 - Lung metastases Year: 2004
Late Breaking Abstract - What do children, parents and paediatricians feel about the risk of growth suppression of inhaled corticosteroids? Source: International Congress 2018 – Paediatric asthma: new insights in its prevalence, treatment and treatment failure Year: 2018
Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021
Oral steroids in asthma: a double-edged sword Source: Eur Respir J, 54 (5) 1902034; 10.1183/13993003.02034-2019 Year: 2019
LATE-BREAKING ABSTRACT: Inhibition of the ubiquitin-E3-ligase FBXW7 enhances steroid efficacy: New concept for treating steroid insensitivity Source: International Congress 2015 – Asthma mechanisms and management Year: 2015
Defining low-dose corticosteroid: the pendulum still oscillates Source: Eur Respir J 2015; 46: 574-576 Year: 2015